# NCT04410796 (NCT04410796)

> Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04410796
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Memorial Sloan Kettering Cancer Center
- Conditions: Metastatic Non-small Cell Lung Cancer
- Interventions: Osimertinib; Carboplatin; Pemetrexed
- Enrollment: 571
- Primary outcome: Determine the progression-free survival

## Indexed commentary on NCT04410796 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04410796